Interested to hear from the value gurus please.
Amgen plans to buy Horizon Therapeutics for about $28 billion in cash, bringing on board two blockbuster drugs to ease the hit the biotech giant faces from biosimilar competition.
https://endpts["DOT"]com/amgen-to-buy-horizon-for-28b-in-the-years-biggest-pharma-takeover/
a) Does a deal like this offer any general value guidance IF MSB can deliver on it's lead programs?
b) Does this signal the big pharma sector is slipping into deal mode?
For the Number Crunches
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
-0.025(2.17%) |
Mkt cap ! $1.284B | |||
| Open | High | Low | Value | Volume |
| $1.15 | $1.16 | $1.11 | $7.363M | 6.488M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 94863 | $1.13 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.13 | 5000 | 2 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |